Based on clinical trials, PD-1/PD-L1 inhibitors have an effective rate of 80% against lymphoma and 60% against high-microsatellite instability (MSIH) neoplasms, and efficacy for other solid tumors ranges from 10% to 30% (Li et al., 2022). Here, CD274 is linked to neoplasm.